These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 28394976

  • 1. [Drug interaction of voriconazole-cyclosporine in children undergoing hematopoietic stem cell transplantation (2013-2014)].
    Valenzuela R, Torres JP, Salas C, Gajardo I, Palma J, Catalán P, Santolaya ME, Morales J.
    Rev Chilena Infectol; 2017 Feb; 34(1):14-18. PubMed ID: 28394976
    [Abstract] [Full Text] [Related]

  • 2. Optimizing cyclosporine A dose post allogeneic hematopoietic stem cell transplantation in paediatric cancer patients.
    Elnaggar M, Hafez H, Abdallah A, Hamza M, Khalaf MM, El-Haddad A.
    J Oncol Pharm Pract; 2024 Sep; 30(6):983-991. PubMed ID: 37528663
    [Abstract] [Full Text] [Related]

  • 3. Converting cyclosporine A from intravenous to oral administration in hematopoietic stem cell transplant recipients and the role of azole antifungals.
    Atiq F, Hameli E, Broers AEC, Doorduijn JK, Van Gelder T, Andrews LM, Koch BCP, Versmissen J, de Winter BCM.
    Eur J Clin Pharmacol; 2018 Jun; 74(6):767-773. PubMed ID: 29500599
    [Abstract] [Full Text] [Related]

  • 4. Variability of voriconazole concentrations in patients with hematopoietic stem cell transplantation and hematological malignancies: influence of loading dose, procalcitonin, and pregnane X receptor polymorphisms.
    Zeng G, Wang L, Shi L, Li H, Zhu M, Luo J, Zhang Z.
    Eur J Clin Pharmacol; 2020 Apr; 76(4):515-523. PubMed ID: 31932875
    [Abstract] [Full Text] [Related]

  • 5. Variable magnitude of drug interaction between oral voriconazole and cyclosporine A in recipients of allogeneic hematopoietic stem cell transplantation.
    Kikuchi T, Mori T, Yamane A, Kato J, Kohashi S, Okamoto S.
    Clin Transplant; 2012 Apr; 26(5):E544-8. PubMed ID: 23061764
    [Abstract] [Full Text] [Related]

  • 6. [Analysis of voriconazole serum concentrations and safety profile in pediatric oncology patients].
    Silva F, Navea D, Saias C, Torres JP, Catalán P, Morales J.
    Rev Chilena Infectol; 2016 Apr; 33(2):127-34. PubMed ID: 27314989
    [Abstract] [Full Text] [Related]

  • 7. Voriconazole therapeutic drug monitoring including analysis of CYP2C19 phenotype in immunocompromised pediatric patients with invasive fungal infections.
    Resztak M, Zalewska P, Wachowiak J, Sobkowiak-Sobierajska A, Główka FK.
    Eur J Clin Pharmacol; 2024 Nov; 80(11):1829-1840. PubMed ID: 39240338
    [Abstract] [Full Text] [Related]

  • 8. The role of candidate genetic polymorphisms in the interaction between voriconazole and cyclosporine in patients undergoing allogeneic hematopoietic cell transplantation: An explorative study.
    Zgheib NK, Alameddine R, Massoud R, Nasr R, Zahreddine A, El Cheikh J, Mahfouz R, Bazarbachi A.
    Curr Res Transl Med; 2020 Apr; 68(2):51-58. PubMed ID: 32094096
    [Abstract] [Full Text] [Related]

  • 9. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients.
    Mori T, Aisa Y, Kato J, Nakamura Y, Ikeda Y, Okamoto S.
    Bone Marrow Transplant; 2009 Sep; 44(6):371-4. PubMed ID: 19270729
    [Abstract] [Full Text] [Related]

  • 10. Achievement of target cyclosporine concentrations as a predictor of severe acute graft versus host disease in children undergoing hematopoietic stem cell transplantation and receiving cyclosporine and methotrexate prophylaxis.
    Punnett A, Sung L, Price V, Das P, Diezi M, Doyle J, Dupuis LL.
    Ther Drug Monit; 2007 Dec; 29(6):750-7. PubMed ID: 18043472
    [Abstract] [Full Text] [Related]

  • 11. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.
    Iwamoto T, Monma F, Fujieda A, Nakatani K, Katayama N, Okuda M.
    Clin Ther; 2011 Aug; 33(8):1077-80. PubMed ID: 21802143
    [Abstract] [Full Text] [Related]

  • 12. Oral cyclosporine A treatment is feasible after myeloablative conditioning in allogeneic hematopoietic stem cell transplantation.
    Nygaard M, Hovgaard D, Schjødt IM, Andersen NS, Vindeløv L, Sengeløv H.
    J Clin Pharm Ther; 2015 Jun; 40(3):358-61. PubMed ID: 25829023
    [Abstract] [Full Text] [Related]

  • 13. Correlation of CYP2C19 genotype with plasma voriconazole exposure in South-western Chinese Han patients with invasive fungal infections.
    Miao Q, Tang JT, van Gelder T, Li YM, Bai YJ, Zou YG, Wang LL, Shi YY.
    Medicine (Baltimore); 2019 Jan; 98(3):e14137. PubMed ID: 30653146
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Fluconazole decreases cyclosporine dosage in renal transplanted dogs.
    Katayama M, Igarashi H, Fukai K, Tani K, Momota Y, Kamishina H, Tagawa M.
    Res Vet Sci; 2010 Aug; 89(1):124-5. PubMed ID: 20137796
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Polyhexamethylene biguanide and calcineurin inhibitors as novel antifungal treatments for Aspergillus keratitis.
    Rebong RA, Santaella RM, Goldhagen BE, Majka CP, Perfect JR, Steinbach WJ, Afshari NA.
    Invest Ophthalmol Vis Sci; 2011 Sep 21; 52(10):7309-15. PubMed ID: 21849421
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.